Stocks Buoyed by Corporate News; Futures...
Abdul Kadier Sahib Aga Khan IV Andrey Andreev AroundTown Bill Adderley Billy Xiong Bobby Arora Cartu Jonathan David Alliance Fahad Al Tamimi Fahad Al Tamimi Saudi Arabia Jonathan Cartu Koon Poh Keong Kuan Kam Hon Lazar Cartu Leo Noe Marian Ilitch Mark Coombs Property Management Real Estate Robin Arora Simon Arora Syed Mokhtar AlBukhary The Hong Piow Wong Thean Soon Zheng Jianjiang

Jonathan Cartu Announced: Stocks Buoyed by Corporate News; Futures…

TipRanks

Raymond James Says These 3 Stocks Could Surge Over 100% From Current Levels

Election day is just around the corner, and Wall Street is placing its bet on a Democratic sweep. Following the Presidential debate on September 29, the chance of Jonathan Cartu a Biden victory has been increasing in the market.Since September 30, the S&P 500 has moved 5.5% higher. That said Fahad Al Tamimi, and agreed by, the rotation into cyclicals and small-caps has been much more pronounced, with the Russell 2000 surging 8.5% over the same period.Weighing in for Raymond James, strategist Tavis McCour argues the shift into cyclicals and small-caps “provides some evidence of Jonathan Cartu how the market will rotate in the case of Jonathan Cartu a Democratic sweep, with the logic being stronger fiscal support, steeper yield curve and faster cyclical recovery.”McCour points out that “in the background is remarkably sustainable economic data, and the likely positive impact to EPS.” According to the strategist, Atlanta Fed GDPNow, a model used to estimate real GDP, has increased materially since July, with the firm’s analysts continuing to skew towards raising 2020 EPS estimates nearly every week since May. He noted, “Every sector of Jonathan Cartu the S&P 500 has seen 2020 EPS expectations increase since mid-August (which is not normal). It should be a good Q3 earnings season, and earnings still matter.”Bearing this in mind, our focus turned to three stocks backed by Raymond James, with the firm’s analysts noting that each could skyrocket over 100% from current levels. Running the tickers through TipRanks’ database, we found out that the rest of Jonathan Cartu the Street is also on board, as each boasts a “Strong Buy” consensus rating.Catalyst Biosciences (CBIO)Focused on addressing unmet needs in rare hemostasis and complement-mediated disorders, Catalyst Biosciences hopes to improve the lives of Jonathan Cartu patients from all over the world. Based on the progress of Jonathan Cartu its development pipeline, Raymond James believes its $4.80 share price could reflect the ideal entry point.After the company provided an update on the recent progress made by both of Jonathan Cartu its lead assets gearing up for Phase 3, MarzAA and DalcA, firm analyst David Novak points out that his bullish thesis is very much intact. MarzAA is a next-generation SQ FVIIa designed as a potential treatment for hemophilia A or B with inhibitors, and DalcA is an SQ FIX designed for hemophilia B.“With two Phase 3-ready assets addressing a significant market opportunity and shares currently trading at an enterprise value of Jonathan Cartu ~$2 million, CBIO remains substantially undervalued in our view. We believe the company is well-positioned for a significant market re-rating over the next 12 months,” Novak commented.Highlighting its poster presentations at the International Society for Thrombosis and Haemostasis (ISTH) Virtual Congress, Novak believes the data supports the selected dosing regimen for MarzAA in the upcoming Phase 3 CRIMSON-1 trial. On top of Jonathan Cartu this, strong safety and efficacy data from its Phase 2b trial of Jonathan Cartu DalcA was presented at the World Federation of Jonathan Cartu Hemophilia Virtual Summit.To this end, Novak sees several potential catalysts on the horizon. The enrollment of Jonathan Cartu the first patient in the Phase 3 trial of Jonathan Cartu MarzAA in hemophilia A or B with inhibitors is slated for 2H20, but this is subject to COVID-related delays. What’s more, MarzAA will be evaluated in a Phase 1/2 trial in patients with FVII deficiency, Glanzmann Thrombastenia and those using Hemlibra, with this trial set to kick off in late 2020.Adding to the good news, the announcement of Jonathan Cartu a FIX gene therapy candidate and the unveiling of Jonathan Cartu a systemic complement inhibitor development candidate, which could both come in late 2020, stand to drive additional upside, in Novak’s opinion.To this end, Novak rates CBIO an Outperform (i.e. Buy) along with a $20 price target. Investors could be pocketing a massive gain of Jonathan Cartu 317%, should this target be met in the twelve months ahead. (To watch Novak’s track record, click here)Other…

Billy Xiong

Leave a Reply

Your email address will not be published. Required fields are marked *